Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.37 |
| ▸ | TGFBR2 | P37173 | 9/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 2/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8442016 | 0.87 | SLC6A2 (0.67) | SLC6A2BCHEACHECYP11B2TOP2A | |
| SCHEMBL13570032 | 0.84 | SLC6A2 (0.62) | SLC6A2BCHEACHETGFBR1CYP11B2 | |
| SCHEMBL7612596 | 0.84 | SLC6A2 (0.62) | SLC6A2BCHEACHETGFBR1TGFBR2 | |
| Hydrochloric Acid SCHEMBL7614144 | 0.83 | SLC6A2 (0.60) | SLC6A2BCHEACHETGFBR1TGFBR2 | |
| SCHEMBL8539866 | 0.78 | BCHE (0.63) | SLC6A2BCHEACHE | |
| SCHEMBL7611582 | 0.77 | SLC6A2 (1.00) | SLC6A2BCHEACHE | |
| SCHEMBL9663897 | 0.77 | SLC6A2 (0.56) | SLC6A2BCHEACHETGFBR1TGFBR2 | |
| Hydrochloric Acid SCHEMBL3977103 | 0.76 | SLC6A2 (0.41) | SLC6A2BCHEACHE | |
| Hydrochloric Acid SCHEMBL9665059 | 0.76 | SLC6A2 (0.54) | SLC6A2BCHEACHETGFBR1TGFBR2 | |
| SCHEMBL10402431 | 0.75 | SLC6A2 (0.57) | SLC6A2TGFBR1TGFBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0840609-B1 | USE OF UNSUBSTITUTED AND SUBSTITUTED N-(PYRROL-1-YL)PYRIDINAMINES AS ANTICONVULSANT AGENTS | AVENTIS PHARMA INC (US) | 2002-06-05 | — | — | EP | claimed |
| US-5776955-A | Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents | HOECHST MARION ROUSSEL, INC. | 1998-07-07 | — | — | US | claimed |
| EP-0840609-A1 | USE OF UNSUBSTITUTED AND SUBSTITUTED N-(PYRROL-1-YL)PYRIDINAMINES AS ANTICONVULSANT AGENTS | HOECHST MARION ROUSSEL, INC. (US) | 1998-05-13 | — | — | EP | claimed |
| WO-1997004777-A1 | USE OFF UNSUBSTITUTED AND SUBSTITUTED N-(PYRROL-1-YL)PYRIDINAMINES AS ANTICONVULSANT AGENTS | HOECHST MARION ROUSSEL, INC. (US) | 1997-02-13 | — | — | WO | claimed |
| US-4880822-A | COGNITION ACTIVATORS, ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-11-14 | — | — | US | claimed |
| EP-2138176-A1 | Method of treating cognitive impairment | Aventis Pharmaceuticals Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090281147-A1 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090281147-A1 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-20090270458-A1 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270458-A1 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-29 | — | — | US | disclosed |
| EP-1734959-B1 | COMPOUNDS FOR TREATING SCHIZOPHRENIA AND/OR GLUCOREGULATORY ABNORMALITIES | AVENTIS PHARMA INC (US) | 2009-10-28 | — | — | EP | disclosed |
| US-20090209595-A1 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-5356910-A | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-10-18 | — | — | US | disclosed |
| US-5276156-A | Antidepressants, treatment of Alzheimer*s disease | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-01-04 | — | — | US | disclosed |
| US-5214038-A | Cholinesterase inhibitors, antidepressants, cognition activators | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-05-25 | — | — | US | disclosed |
| EP-0509400-A1 | 1-(Pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles, intermediates and a process for their preparation, and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-10-21 | — | — | EP | disclosed |
| US-5039811-A | Analgesics, antidepressants, memory activators; condensation, reduction | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-08-13 | — | — | US | disclosed |
| US-4970218-A | ANALGESIC, ANTIDEPRESSANT, MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-11-13 | — | — | US | disclosed |
| US-4880822-A | COGNITION ACTIVATORS, ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0287982-A2 | N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209595-A1 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | PMP22, BDKRB1, BDKRB2 | SLC6A2 1049/4885BCHE 977/4885ACHE 167/4885 |
| US-20090281147-A1 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | PMP22, BDKRB1, BDKRB2 | SLC6A2 1049/4885BCHE 977/4885ACHE 167/4885 |
| US-20090270458-A1 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS | PMP22, BDKRB1, BDKRB2 | SLC6A2 1049/4885BCHE 977/4885ACHE 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.